Article
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
European urology - 1 Mar 2017
Hsieh James J, Chen David, Wang Patricia I, Marker Mahtab, Redzematovic Almedina, Chen Ying-Bei, Selcuklu S Duygu, Weinhold Nils, Bouvier Nancy, Huberman Kety H, Bhanot Umesh, Chevinsky Michael S, Patel Parul, Pinciroli Patrizia, Won Helen H, You Daoqi, Viale Agnes, Lee William, Hakimi A Ari, Berger Michael F, Socci Nicholas D, Cheng Emily H, Knox Jennifer, Voss Martin H, Voi Maurizio, Motzer Robert J
Abstract excerpt
BACKGROUND: Metastatic renal cell carcinoma (RCC) patients are commonly treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin inhibitors. Correlations between somatic mutations and first-line targeted therapy outcomes have not been reported on a randomized trial. OBJECTIVE: To evaluate the relationship between tumor mutations and treatment outcomes in RECORD-3, a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.